Krystal Biotech, Inc. (KRYS): Total Assets
$1.33B
As of 2025-12-31
$1.50B
As of 2026-06-30
+33.7%
3-year compound annual growth
+33.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.33B | +26.3% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $1.06B | +29.0% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $818.36M | +46.5% | 2025-02-19, Balance as of period end |
| 2022-12-31 | $558.45M | -10.8% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $626.29M | +101.5% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $310.84M | +48.7% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $209.02M | +80.0% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $116.12M | +131.7% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $50.11M | n/m | 2018-03-12, Balance as of period end |
| 2016-12-31 | $2.18M | n/a | 2018-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.33B | +26.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $1.07B | +5.7% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $641.86M | +4.5% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $562.16M | +49.1% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $624.24M | +27.7% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $512.74M | -4.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $487.97M | +12.8% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $913.17M | +0.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
Compare KRYS, IMCR, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗